Novel treatments for catecholaminergic polymorphic ventricular tachycardia: a translational study from single cells to patients
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder characterised by the onset of irregular heart rhythm during exertion. This irregular heart rhythm (often a ventricular arrhythmia) can cause collapse and sudden cardiac death. The treatment that is currently available is effective in only 70% of cases. Recently two agents (flecainide and a form of fatty acid called PUFA) have emerged as potential treatments for CPVT. In this Intermediate Clinical Research Fellowship, Dr Luigi Venetucci will test these two treatments. He will study the treatments in two mouse models of CPVT and in patients with the disorder. The aim of the fellowship is to determine if these treatments are effective and the mechanisms responsible for whether they work or not.
Project details
| Grant amount | £697,469 |
|---|---|
| Grant type | Fellowships |
| Application type | Intermediate Clinical Research Fellowship |
| Start Date | 01 February 2011 |
| Duration | 5 years |
| Reference | FS/10/63/28374 |
| Status | Complete |
